Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$7.96 0.00 (0.00%) as of 4:30 Wed 9/18


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.51(B)
Last Volume: 1,754,233 Avg Vol: 4,315,920
52 Week Range: $4.13 - $8.69
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  1115
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 183,601 183,601 183,601
Total Buy Value $0 $1,048,338 $1,048,338 $1,048,338
Total People Bought 0 10 10 10
Total Buy Transactions 0 10 10 10
Total Shares Sold 0 11,387 11,387 506,586
Total Sell Value $0 $69,059 $69,059 $6,068,300
Total People Sold 0 2 2 10
Total Sell Transactions 0 2 2 16
End Date 2024-06-23 2024-03-22 2023-09-22 2022-09-22

   
Records found: 755
  Page 21 of 31  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-03-14 4 S $11.24 $35,125 D/D (3,125) 126,616     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-03-14 4 OE $4.73 $14,781 D/D 3,125 129,741     -
   Lee Kenneth B Jr Director   •       •      –    2014-03-06 4 S $12.69 $160,719 D/D (12,665) 10,252     -
   Lee Kenneth B Jr Director   •       •      –    2014-03-06 4 OE $3.80 $87,085 D/D 22,917 22,917     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2014-03-04 4 S $12.57 $510,870 D/D (40,642) 208,195     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2014-03-04 4 OE $4.30 $241,177 D/D 28,816 248,837     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-03-04 4 S $12.63 $514,470 D/D (40,734) 71,622     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-03-04 4 OE $1.42 $124,897 D/D 31,174 112,356     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-03-04 4 S $12.69 $38,070 D/D (3,000) 126,616     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-03-04 4 OE $4.73 $14,190 D/D 3,000 129,616     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2014-03-01 4 D $11.69 $18,914 D/D (1,618) 220,021     -
   Stonehouse Jon P President & CEO   •       •      –    2014-03-01 4 D $11.69 $59,829 D/D (5,118) 630,242     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-03-01 4 D $11.69 $12,742 D/D (1,090) 81,182     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-03-01 4 D $11.69 $5,389 D/D (461) 126,616     -
   Sheridan William P Senior VP - CMO   •       •      –    2014-03-01 4 D $11.69 $20,329 D/D (1,739) 137,122     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2014-02-24 4 D $12.20 $99,674 D/D (8,170) 221,639     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2014-02-24 4 OE $4.30 $99,670 D/D 23,179 229,809     -
   Sheridan William P SR VP - CMO   •       •      –    2014-01-20 4 A $0.00 $0 D/D 54,000 136,539     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-01-20 4 A $0.00 $0 D/D 54,000 126,218     -
   Stonehouse Jon P President & CEO   •       •      –    2014-01-20 4 A $0.00 $0 D/D 128,000 632,360     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-01-20 4 A $0.00 $0 D/D 27,000 81,487     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2014-01-20 4 A $0.00 $0 D/D 54,000 206,630     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-01-14 4 D $10.87 $16,207 D/D (1,491) 54,487     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-01-14 4 OE $1.20 $16,200 D/D 13,500 55,978     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-01-13 4 D $10.55 $133,152 D/D (12,621) 72,218     -
  755 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 21 of 31
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us